- Home
- VRDN vs TARS Comparison
VRDN vs TARS Comparison
Compare VRDN & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRDN
- TARS
- Stock Information
- Founded
- VRDN 2006
- TARS 2016
- Country
- VRDN United States
- TARS United States
- Employees
- VRDN N/A
- TARS N/A
- Industry
- VRDN Medical Specialities
- TARS Medicinal Chemicals and Botanical Products
- Sector
- VRDN Health Care
- TARS Health Care
- Exchange
- VRDN Nasdaq
- TARS Nasdaq
- Market Cap
- VRDN 1.5B
- TARS 1.8B
- IPO Year
- VRDN N/A
- TARS 2020
- Fundamental
- Price
- VRDN $20.14
- TARS $44.83
- Analyst Decision
- VRDN Strong Buy
- TARS Strong Buy
- Analyst Count
- VRDN 10
- TARS 5
- Target Price
- VRDN $37.25
- TARS $54.20
- AVG Volume (30 Days)
- VRDN 1.1M
- TARS 1.1M
- Earning Date
- VRDN 11-12-2024
- TARS 11-13-2024
- Dividend Yield
- VRDN N/A
- TARS N/A
- EPS Growth
- VRDN N/A
- TARS N/A
- EPS
- VRDN N/A
- TARS N/A
- Revenue
- VRDN $302,000.00
- TARS $129,621,000.00
- Revenue This Year
- VRDN N/A
- TARS $852.60
- Revenue Next Year
- VRDN N/A
- TARS $74.21
- P/E Ratio
- VRDN N/A
- TARS N/A
- Revenue Growth
- VRDN N/A
- TARS 801.96
- 52 Week Low
- VRDN $11.40
- TARS $15.60
- 52 Week High
- VRDN $27.20
- TARS $52.99
- Technical
- Relative Strength Index (RSI)
- VRDN 36.38
- TARS 57.98
- Support Level
- VRDN $22.40
- TARS $46.22
- Resistance Level
- VRDN $27.20
- TARS $52.99
- Average True Range (ATR)
- VRDN 1.36
- TARS 3.62
- MACD
- VRDN -0.41
- TARS -0.33
- Stochastic Oscillator
- VRDN 6.37
- TARS 42.09
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.